Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: CpG-7909, Coley.

Stéphane Paul1

  • 1Transgene SA, 2 Rue Adolphe Hirn, Strasbourg 67082, France. paul@transgene.fr

Current Opinion in Molecular Therapeutics
|November 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging interest of anti-integrin αvβ6 antibodies for the diagnosis and prognosis of IBD and primary sclerosing cholangitis at the gut-liver interface.

Inflammatory bowel diseases·2026
Same author

Systems serology identifies FcR-related autoantibody signatures and functions for Sjögren's syndrome.

EMBO molecular medicine·2026
Same author

Current status of intranasal and inhaled COVID-19 vaccines.

NPJ vaccines·2026
Same author

Postpandemic adjuvants to tailor vaccine-induced immunity.

Trends in immunology·2026
Same author

[Long COVID: therapeutic challenges and opportunities in the face of persistent sequelae].

Medecine sciences : M/S·2025
Same author

Anorexia nervosa symptoms are induced after specific gut microbiota dysbiosis transfer in germ-free mice.

Gut microbes·2025
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Coley Pharmaceutical is developing CpG-7909 (ProMune) as a cancer treatment and vaccine adjuvant. This immunotherapy is currently in Phase II clinical trials for melanoma and as a vaccine adjuvant.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Coley Pharmaceutical is developing CpG-7909 (ProMune), an immunotherapy agent.
  • CpG-7909 has potential applications in cancer treatment and as a vaccine adjuvant.

Purpose of the Study:

  • To evaluate the efficacy and safety of CpG-7909 in cancer patients.
  • To assess CpG-7909's role as a vaccine adjuvant.

Main Methods:

  • CpG-7909 has undergone Phase I/II trials for cancer treatment since April 2000.
  • Phase I trials in combination with rituximab for non-Hodgkin's lymphoma began in March 2002.
  • Phase II trials as a vaccine adjuvant commenced by October 2002.
  • Ongoing Phase II trials for melanoma.

Related Experiment Videos

Main Results:

  • Clinical trial data is not detailed in the provided abstract.
  • The abstract focuses on the developmental stages and trial progression of CpG-7909.

Conclusions:

  • CpG-7909 (ProMune) is under active clinical investigation for multiple indications.
  • Further results from ongoing trials are necessary to determine its therapeutic value.